Key Points Interested in Agenus Inc.? Here are five stocks we like better. Agenus is prioritizing its Phase 3 ROBBIN trial of ...
Kelun scores sac-TMT win in first-line NSCLC population missing from Merck’s massive phase 3 program
The clinical blueprint for Merck & Co.’s prized TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), ...
MarketBeat on MSN
Biogen backs Alzheimer's tau drug for phase 3 despite trial miss
MarketBeat Week in Review – 05/18 - 05/22 Biogen (NASDAQ:BIIB) said data from its Phase 2 CELIA study of diranersen in early ...
The planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density ...
Zasocitinib showed superiority over placebo in phase 3 trials, achieving rapid and sustained skin clearance in plaque psoriasis. The trials demonstrated a favorable safety profile, with common adverse ...
A premium-priced private placement gives Agenus $85 million upfront as it shifts resources to one colon-cancer trial.
Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...
Brepocitinib is a first-in-class, oral, selective TYK2–JAK1 inhibitor that blocks cytokine signaling, which has been implicated in dermatomyositis. In this phase 3, double-blind, randomized, ...
Investigational n.c.a. 177Lu-edotreotide (ITM-11) demonstrated a significantly higher progression-free survival and objective response rate vs. everolimusGarching / Munich, July 7, 2026- ITM Isotope ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results